About 2,760,000 results
- Merck Employees FCU
Loans · Auto · New Auto · Used Auto · Consumer · Motorcycles · Boats/Airplanes/RVs · Secured · Unsecured.
4 days ago
The New Yorker has an article about Merck's discovery and development of suvorexant, their orexin inhibitor for insomnia. It also goes into the (not completely reassuring) history of zolpidem (known under the brand name of ...
5 days ago by Pharma Reports
Merck & Co., Inc. (NYSE:MRK): Merck: The Good, The Bad And The Ugly.
2 days ago
Germany's Merck KGaA has announced plans to buy AZ Electronic Materials, which supplies high-tech materials for the electronics industry, for about 1.6 billion pounds ($2.6 billion).
5 days ago
Forest to Acquire U.S. Marketing Rights to Saphris (asenapine) from Merck Forest acquires exclusive rights to Saphris in the United States for the treatment of.
29 Nov 2013
Merck & Co has announced plans to shutter a plant in Ireland by the end of 2017 which will affect 570 staff. The drugs giant, known as MSD outside the USA, says the closure of the facility in Swords, Co Dublin, is the result of ...
29 Nov 2013 by Zacks Equity Research
Merck, which has a strong presence in the diabetes market, continues to focus on developing its portfolio for other indications.
5 days ago by Dan.Stanton@wrbm.com (Dan Stanton)
Trust, transparency and end-to-end participation are just some of the reasons Merck Serono says its exclusive strategic partnership with Quintiles is the “first of its kind.”
5 days ago by Eric Palmer
Merck two months ago laid out plans for its fourth restructuring in 5 years, saying it would whack 8500 jobs from its R&D and commercial operations and cut $2.5 billion in costs globally. And global the cuts have been, with 130 ...
3 days ago by Chemjobber
From the Organic Process Research and Development ASAP stream, a overview of Merck's internal reviews for safety at prep scale  (as defined as 500 grams to 5 kilograms). It partially stemmed from an incident with a ...
19 Nov 2013
More than 80 per cent of advanced melanoma patients treated with Merck & Co's anti-PD-1 therapy MK-3475 were still alive after one year, according to new clinical data. The first survival data from Merck's ongoing phase Ib ...